Latest News

Australian company Noxopharm updates on pipeline November 21, 2019

Emerging Australian oncology company Noxopharm (ASX:NOX) has used its annual general meeting to update investors on its pipeline.

European approval for Starpharma's VivaGel condom November 21, 2019

Starpharma (ASX:SPL) has announced it has been granted marketing approval for its VivaGel condom in Europe.

Imugene appoints world-renowned surgeon to advisory board November 21, 2019

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Professor Prasad S. Adusumilli, MD FACS FCCP, to its newly formed oncolytic virotherapy Scientific Advisory Board.

Antisense Therapeutics announces presentation of additional ATL1102 data November 19, 2019

Antisense Therapeutics (ASX:ANP) has announced the presentation of additional data from seven patients who have completed their 24 weeks of dosing in the ATL1102 phase 2 DMD clinical trial.

Cochlear confirms FDA clearance for Osia 2 System November 19, 2019

Cochlear said it will commence the commercial rollout of the system in the US during the second half of FY20, with availability in other countries subject to regulatory approvals.

Research reveals no link between statins and memory loss November 19, 2019

The release of research conducted over six years has found no link between cholesterol-lowering statins and memory loss.

Greg Hunt announces funding for research into rare cancers and disease November 19, 2019

Health minister Greg Hunt has announced what he describes as the "largest investment in clinical trials in any single round in Australian history".

Zelda cannabis formulations to be supplied to the CARE NSW trial November 14, 2019

Zelda Therapeutics (ASX:ZLD) has entered a new agreement with the NHMRC-funded Australian Centre for Clinical Cannabinoid Research Excellence, based at the University of Newcastle, to commercially supply a cannabis oil formulation.

AVITA Medical announces $120m placement November 14, 2019

Australian regenerative medicine company AVITA Medical (ASX:AVH) has announced an institutional placement of $120 million to fund pipeline development of new indications.

Biotron secures $5.1m underwriting agreement November 12, 2019

Biotron (ASX BIT) has announced it has entered an Option Underwriting Agreement with Gleneagle Securities.

Bridge Program announces 2019 pitch winners November 12, 2019

The Bridge Program has announced the winners of its Pitch Competition following its three-day symposium in Melbourne.

New board appointment for Ellume November 12, 2019

Digital diagnostic company Ellume has announced the appointment of Joanne Moss to its board as an independent non-executive director and chair of audit and risk.

Most Read

More biotech companies moving into ASX 200

European approval for Starpharma's VivaGel condom

Imugene appoints world-renowned surgeon to advisory board

Australian company Noxopharm updates on pipeline

Antisense completes dosing in phase two ATL1102 trial

New Stories

Australian company Noxopharm updates on pipeline

European approval for Starpharma's VivaGel condom

Imugene appoints world-renowned surgeon to advisory board

More biotech companies moving into ASX 200

Antisense completes dosing in phase two ATL1102 trial

Antisense Therapeutics announces presentation of additional ATL1102 data

Cochlear confirms FDA clearance for Osia 2 System

Sign In

Most Read

More biotech companies moving into ASX 200

European approval for Starpharma's VivaGel condom

Imugene appoints world-renowned surgeon to advisory board

Australian company Noxopharm updates on pipeline

Antisense completes dosing in phase two ATL1102 trial

Follow Us

New Stories

Australian company Noxopharm updates on pipeline

European approval for Starpharma's VivaGel condom

Imugene appoints world-renowned surgeon to advisory board

More biotech companies moving into ASX 200

Antisense completes dosing in phase two ATL1102 trial

Antisense Therapeutics announces presentation of additional ATL1102 data

Cochlear confirms FDA clearance for Osia 2 System